Deltec Asset Management LLC Makes New $304,000 Investment in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Deltec Asset Management LLC bought a new stake in Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 100,000 shares of the biopharmaceutical company's stock, valued at approximately $304,000. Deltec Asset Management LLC owned 0.10% of Revance Therapeutics at the end of the most recent quarter.

Several other large investors also recently modified their holdings of RVNC. FORA Capital LLC bought a new stake in Revance Therapeutics in the 3rd quarter valued at $54,000. Creative Planning bought a new stake in shares of Revance Therapeutics in the third quarter valued at about $56,000. Sei Investments Co. boosted its position in shares of Revance Therapeutics by 52.5% during the second quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 7,628 shares during the period. Accredited Investors Inc. acquired a new position in shares of Revance Therapeutics during the third quarter worth about $67,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Revance Therapeutics during the third quarter worth about $88,000. 97.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Barclays reduced their price target on Revance Therapeutics from $7.00 to $3.00 and set an "equal weight" rating for the company in a research report on Monday, December 23rd. HC Wainwright restated a "neutral" rating and set a $6.60 target price on shares of Revance Therapeutics in a report on Friday, November 8th. Mizuho lowered their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a "neutral" rating on the stock in a research note on Tuesday, December 10th. Needham & Company LLC reissued a "hold" rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Finally, StockNews.com initiated coverage on Revance Therapeutics in a report on Thursday. They issued a "hold" rating for the company. Nine analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, Revance Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $8.39.

Revance Therapeutics Stock Performance

Revance Therapeutics stock remained flat at $3.65 during midday trading on Friday. The company's 50 day moving average is $3.39 and its two-hundred day moving average is $4.58. The company has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.90. Revance Therapeutics, Inc. has a 52-week low of $2.30 and a 52-week high of $7.56.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. Analysts expect that Revance Therapeutics, Inc. will post -1.57 earnings per share for the current year.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.